{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027472","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.645047+00:00","generated_at":"2026-06-22T17:51:39.355465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion Q3 2022 product rev $14.0M (+28% Y/Y); net loss $55.1M; CLEAR Outcomes trial finished","bullets":["U.S. net product revenue $14.0M (up 28% YoY); total revenue $19.0M (up 32% YoY).","Net loss $55.1M ($0.81 diluted EPS) vs $69.4M loss ($2.62 EPS) in Q3 2021.","CLEAR Outcomes trial achieved last patient last visit in Oct 2022; topline results expected Jan 2023.","SG&A down 36% YoY to $25.0M; R&D up 15% to $29.1M; cash $239.3M (down $70M from Dec 2021).","Reaffirmed FY2022 OpEx guidance: total $220-240M including $25M stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027472","json":"https://secwatch.observer/filing/0001628280-22-027472.json","markdown":"https://secwatch.observer/filing/0001628280-22-027472.md","text":"https://secwatch.observer/filing/0001628280-22-027472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/0001628280-22-027472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/espr-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T17:51:39.355465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6ef672110e3af96aab19501dfd0be9f6bc271e1","claim":"Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.0 million, net income net losses of $55.1 million, EPS $0.81. Guidance reaffirmed.","evidence_excerpt":"Total revenue for the third quarter ended September 30, 2022, was $19.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/0001628280-22-027472-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$19.0 million"},{"label":"Net income","value":"net losses of $55.1 million"},{"label":"EPS","value":"$0.81"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}